Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
2.100
+0.250 (13.51%)
At close: Jun 27, 2025, 4:00 PM
2.110
+0.010 (0.48%)
After-hours: Jun 27, 2025, 4:33 PM EDT
Elutia Revenue
Elutia had revenue of $6.03M in the quarter ending March 31, 2025, a decrease of -9.92%. This brings the company's revenue in the last twelve months to $23.71M, down -5.33% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.71M
Revenue Growth
-5.33%
P/S Ratio
2.47
Revenue / Employee
$464,922
Employees
51
Market Cap
86.34M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ELUT News
- 2 days ago - Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards - GlobeNewsWire
- 4 weeks ago - Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method - GlobeNewsWire
- 6 weeks ago - Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - GlobeNewsWire
- 2 months ago - Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - GlobeNewsWire
- 2 months ago - Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - GlobeNewsWire
- 2 months ago - Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 - GlobeNewsWire
- 2 months ago - Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - GlobeNewsWire